Abstract
Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.
| Original language | English |
|---|---|
| Pages (from-to) | 33-43 |
| Number of pages | 11 |
| Journal | Journal of Parkinson's Disease |
| Volume | 8 |
| Issue number | 1 |
| DOIs | |
| Publication status | Published - 18 Feb 2018 |
Fingerprint
Keywords
- Glycation
- Maillard-reaction
- Parkinson’s disease
- alpha-synuclein
Cite this
}
Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease. / König, Annekatrin; Vicente Miranda, Hugo; Outeiro, Tiago Fleming.
In: Journal of Parkinson's Disease, Vol. 8, No. 1, 18.02.2018, p. 33-43.Research output: Contribution to journal › Review article
TY - JOUR
T1 - Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson's Disease
AU - König, Annekatrin
AU - Vicente Miranda, Hugo
AU - Outeiro, Tiago Fleming
PY - 2018/2/18
Y1 - 2018/2/18
N2 - Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.
AB - Parkinson's disease (PD) is a neurodegenerative disorder with complex etiology and variable pathology. While a subset of cases is associated with single-gene mutations, the majority originates from a combination of factors we do not fully understand. Thus, understanding the underlying causes of PD is indispensable for the development of novel therapeutics. Glycation, the non-enzymatic reaction between reactive dicarbonyls and amino groups, gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). AGEs accumulate over a proteins life-time, and increased levels of glycation reaction products play a role in diabetic complications. It is now also becoming evident that PD patients also display perturbed sugar metabolism and protein glycation, including that of alpha-synuclein, a key player in PD. Here, we hypothesize that anti-diabetic drugs targeting the levels of glycation precursors, or promoting the clearance of glycated proteins may also prove beneficial for PD patients.
KW - Glycation
KW - Maillard-reaction
KW - Parkinson’s disease
KW - alpha-synuclein
U2 - 10.3233/JPD-171285
DO - 10.3233/JPD-171285
M3 - Review article
VL - 8
SP - 33
EP - 43
JO - Journal of Parkinson's Disease
JF - Journal of Parkinson's Disease
SN - 1877-7171
IS - 1
ER -